An Optimized Dual-targeted Anti-angiogenic Therapy Strategy with Regorafenib and Imatinib for Colorectal Cancer by Multi-parametric MRI

Motivation: Regorafenib's limited duration and resistance in CRC treatment necessitate strategies for enhanced efficacy. Goal(s): To evaluate whether alternating regorafenib with imatinib can improve therapeutic outcomes in CRC. Approach: This study used mpMRI to monitor tumor microenvironment changes in CRC models receiving alternating regorafenib/imatinib, focusing on perfusion, hypoxia, and cellular responses. Results: Alternating therapy achieved superior tumor perfusion, sustained hypoxia reduction, and enhanced apoptosis, suggesting potential for improved patient survival and quality of life. Impact: This study demonstrates that alternating regorafenib and imatinib therapy enhances tumor response, prolongs antitumor effects, and overcomes treatment resistance, improving survival outcomes in CRC.